Advertisement

Reactions Weekly

, Volume 1777, Issue 1, pp 126–126 | Cite as

Ibritumomab tiuxetan/ibritumomab tiuxetan-Y-90/rituximab

Various toxicities: 6 case reports
Case report
  • 16 Downloads

Reference

  1. Iino M, et al. Yttrium-90 ibritumomab tiuxetan consolidation versus rituximab maintenance therapy after induction chemotherapy in patients with indolent non-Hodgkin lymphoma: a single-institution experience. Hematology 24: 623-630, No. 1, Dec 2019. Available from: URL: http://doi.org/10.1080/16078454.2019.1664094 - JapanCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations